skip to Main Content
himagine Solutions is now a part of Omega Healthcare. Click here to learn more.

Tumor Tip of the Week-Xgeva

Scenario: 2021 patient presents with metastatic prostate adenocarcinoma to the bones, receiving Xgeva.

Question:  Would you code the Xgeva to Hormone therapy?

  • Yes
  • No

Answer:   No

Rationale: SEER*Rx Interactive Antineoplastic Drugs Database https://seer.cancer.gov/seertools/seerrx/

Xgeva

Category

Ancillary Agent

Biologic therapy (BRM, immunotherapy)

Subcategory

PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD

Prevents bone resorption–do not code

RANKL inhibitor

Primary Site

Bone metastases

Remarks

IMPORTANT CODING NOTE (JULY 12, 2013): This drug was approved by the FDA on June 13, 2013 to treat unresectable giant cell tumors of the bone in both adults and skeletally mature adolescents. If this drug is being prescribed to treat this type of tumor, code as BRM/Immunotherapy. For all other conditions listed in the November release information below, do not code, the drug is considered ancillary.

November 18, 2010: Received FDA approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Back To Top
×Close search
Search
Send this to a friend